Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes

Diabetes Obes Metab. 2017 Jun;19(6):906-908. doi: 10.1111/dom.12885. Epub 2017 Mar 17.

Abstract

Glucagon-like peptide-1 receptor agonist (GLP-1RAs) labels warn about acute pancreatitis (AP) and impose upon doctors the obligation to inform patients about symptoms of AP. Here we systematically reviewed the risk of AP in randomized placebo-controlled trials (RCTs) investigating the effect of GLP-1RAs in type 2 diabetes. We performed a systematic review with meta-analysis of long-term (minimum 24 months), placebo-controlled GLP-1RA RCTs in which AP was a predefined adverse event and adjudicated by blinded and independent adjudicating committees. Three high-quality RCTs included a total of 9347 GLP-1RA-treated and 9353 placebo-treated patients with type 2 diabetes. Compared to placebo, treatment with GLP1-RA was not associated with increased risk of AP (Peto odds ratio 0.745 [95% CI, 0.47-1.17]). Trial Sequential Analysis suggested that additional evidence is needed. In conclusion, this review found no evidence that treatment with GLP-1RA increases the risk of AP in patients with type 2 diabetes.

Keywords: GLP-1 analogue; antidiabetic drug; incretin therapy; liraglutide; meta-analysis; type 2 diabetes.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Acute Disease
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Glucagon-Like Peptide-1 Receptor / agonists*
  • Glucagon-Like Peptides / adverse effects
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Liraglutide / adverse effects
  • Odds Ratio
  • Pancreatitis / chemically induced*
  • Peptides / adverse effects
  • Randomized Controlled Trials as Topic
  • Risk Factors

Substances

  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Peptides
  • semaglutide
  • Glucagon-Like Peptides
  • lixisenatide
  • Liraglutide